2023 INDUCTEE Jean-Lucien Rouleau, MD Patient Care, Leadership in Organizational Development, Heart & Vessels
September 20, 1950
(Ottawa, Ontario)
MD, University of Ottawa (1974)
2022: Rank of Knight | Ordre de Montréal
2020: Institute of Circulatory and Respiratory Health (CIHR-ICRH)/Canadian Cardiovascular Society (CCS) Distinguished Lecturer Award in Cardiovascular Sciences
See All AwardsAwards & Honours:
2022: Rank of Knight | Ordre de Montréal
2020: Institute of Circulatory and Respiratory Health (CIHR-ICRH)/Canadian Cardiovascular Society (CCS) Distinguished Lecturer Award in Cardiovascular Sciences
2016: Order of Canada
2016: PRIX du Professeur Émérite de carrière / Department of Medicine, U de Montréal
2011: Cardiologue Émérite from the Association des cardiologues du Québec
2009: The John Forester Career Achievement Lecture Award of the Institute of Cardiovascular Sciences
2009: The Henry Friesen Award and lecture
2009: Prestige Award from the Quebec Medical Association
2008 – 2020: Fellow, Canadian Academy of Health Sciences
2005: Personnalité de la semaine, La Presse
2005: CCS Annual Achievement Award
1997: Canadian Cardiovascular Career Research Achievement Award
1996 – 1997: Best Teacher, Department of Medicine, Montreal Heart Institute
1992: Centennial Medal of Canada
1984: Fellow of the American College of Cardiology (FACC)
1982: Fellow of the American College of Physicians (FACP)
1982: Finalist, American College of Cardiology, Young Investigator Award
Renowned cardiologist instrumental in developing life-saving medication sacubitril/valsartan for treatment of chronic heart failure.
Jean-Lucien Rouleau has been recognized worldwide for his transformative contributions to cardiology, including translational scientific work in ventricular function, post-infarction ventricular remodelling, and neurohormonal activation. His leadership in clinical research culminated in the development of the life-saving medication sacubitril/valsartan, now routinely used to treat patients with chronic heart failure. As Director of the Institute of Circulatory and Respiratory Health, Dr. Rouleau laid the groundwork for the Strategy for Patient Oriented Research (SPOR), and helped establish networks focusing on respiration, sleep and circadian rhythm, stroke, atrial fibrillation, vascular health and coagulation. As Dean of the Faculty of Medicine, Université de Montréal, he initiated development of a delocalized campus that resolved the lack of needed health care professionals in an underserved region; and championed the development of a patient-partner-public approach to health care education. As a researcher, author, educator, and administrator, Dr. Rouleau has made lasting contributions ranging from medications to health care networks, from medical facilities to improved medical policies and practices. His ongoing service to the cause of accessible and effective public health care now includes a five-year, multi-million dollar grant to lead a nationwide Canada Heart Failure Network.
Key Facts
Pioneered the development of regional campuses in Canada. The campus in Mauricie, Quebec, in partnership with regional academic and health institutions, has helped solve a critical shortage of health professionals in a particularly underserved region.
Building on his translational scientific work in ventricular function and neurohormonal activation, Dr. Rouleau played a key role in developing the life-saving medication sacubitril/valsartan, now routinely used to treat patients with chronic heart failure.
Criss-crossed the country as Director of the Institute of Circulatory and Respiratory Health, meeting with provincial academic and government leaders, to lay the groundwork for the Strategy for Patient Oriented Research (SPOR), currently a flagship program of The Canadian Institutes of Health Research (CIHR).
Created an organization in a Faculty of Medicine, dedicated to patient-led partnerships. The office has been able to deploy its approach to care, research and teaching with more than 250 expert patients involved in more than 120 patient engagement and partnership pilot projects across Montreal, Quebec, and Canada.
Established as director of the Institute of Circulatory and Respiratory Health, national networks in stroke treatment and rehabilitation, vascular diseases, respiratory medicine, sleep, cardiac resuscitation, atrial fibrillation, stroke prevention, coagulation, and critical care.
Professional timeline
Impact on lives today
Heart failure affects upwards of 750,000 Canadians. Dr. Rouleau’s involvement in developing sacubitril/valsartan, now an often life-saving standard medical therapy for heart failure, places him in the front rank of Canadian cardiological research, and his foundational work in establishing Canadian Institutes of Health Research’s Strategy for Patient Oriented Research (SPOR) has helped transform clinical research and patient engagement in Canada.
2023
-
Jean-Lucien Rouleau inducted into the Canadian Medical Hall of Fame
-
Scientific Director of the Institute for Cardiovascular and Respiratory Medicine of CIHR
-
Co-chair, National Academic Health Science Centre Task Force on Securing the Future of Canadian Academic Health Science Centers
Health and Medical Education & Training -
Member, Governing Council, Canadian Institutes for Health Research (CIHR)
-
“Surgical Treatment for Ischemic Heart Failure” (STICH), the biggest heart surgery study ever conducted occurs.
Heart & VesselsAs a result of this study, led by Jean-Lucien Rouleau, many best practices in regard to the use of heart surgery have already been modified.
-
Director of cardiology and of the Cardiovascular Program of the UHN (Munk Cardiac Center) and Mount Sinai Hospital
Leadership in Organizational Development -
Director of the Cardiology Department and Deputy Director of the Research Centre of the University of Sherbrooke
Leadership in Organizational Development
1989
Dr. Rouleau’s contributions to ground-breaking research have had world-recognized impact on the field of cardiology
Additional Resources:
You might also be interested in these Laureates
